TL;DR: Yes, that would be very reasonable.Based on the CLEAR study, the combination of lenvatinib and everolimus has shown improved ORR and PFS compared to sunitinib. However, based on RECORD-3, which everolimus was inferior to sunitinib in an intent to treat population and in a mTOR pathway activat...